Why this exists: the law that blocked Medicare coverage
When Medicare's prescription drug benefit (Part D) was created, the statute specifically excluded “agents when used for anorexia, weight loss, or weight gain” from coverage. That exclusion still stands — which is why, for years, Medicare members paid full retail (over $1,000/month) for Wegovy or Zepbound, or simply went without. The GLP-1 Bridge is a temporary demonstration that steps around that exclusion, at a flat $50/month, to test what broader Medicare coverage would look like. If you have Medicare and have wanted a weight-loss GLP-1, this is the first realistic path — see does Medicare cover Ozempic for weight loss for the wider coverage picture.
Full eligibility: do you qualify?
You need Medicare Part D enrollment plus one of three clinical categories (a provider attests to your category). Meeting any one row qualifies you:
| If your BMI is… | …you also need |
|---|---|
| 35 or higher | Nothing else — BMI ≥35 qualifies on its own |
| 30 or higher | Heart failure, uncontrolled high blood pressure, or chronic kidney disease |
| 27 or higher | Prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease |
Roughly 3.8 million Medicare members — about 8% of Part D enrollees — would have met the full criteria on 2023 claims data (KFF, June 2026). That is a retrospective simulation of who would have qualified, not a forecast of who will enrol. Your provider documents the BMI and the qualifying condition — so make sure your chart reflects both.
Which drugs are covered — and which aren't
Foundayo (orforglipron) — all formulations
Lilly's oral GLP-1 pill, FDA-approved April 2026. The Bridge covers every formulation.
Wegovy — pen and pill
Both the injectable Wegovy pen and the oral Wegovy pill are covered.
Zepbound — KwikPen only
The KwikPen formulation of Zepbound is covered (note: specifically the KwikPen).
Ozempic, Mounjaro, Rybelsus — NOT covered
These are diabetes drugs; Medicare already covers them for type 2 diabetes through normal Part D, so they're not in the Bridge.
How the $50 copay actually works
The mechanics matter, because the Bridge behaves differently from your normal Part D drugs:
- Flat $50/month, any dose. Unlike normal cost-sharing, it doesn't rise as you titrate up.
- Outside your deductible. The $50 doesn't count toward your Part D deductible.
- Outside the out-of-pocket cap. It doesn't count toward the annual cap ($2,100 in 2026, $2,400 in 2027) — so it won't push your other drugs into catastrophic coverage sooner.
- No Extra Help. If you get the Part D Low-Income Subsidy, you can't apply it to Bridge drugs — you still pay the $50.
How to get it: step by step
- Confirm Part D enrollment. You must be in a Medicare Part D plan (stand-alone or through Medicare Advantage with drug coverage).
- See a provider and document your category. Your prescriber records your BMI and the qualifying condition, and confirms you meet one of the three categories.
- Get an eligible prescription. Wegovy, Zepbound KwikPen, or Foundayo — not Ozempic/Mounjaro.
- Fill it and pay $50. There's no separate beneficiary enrollment; the pharmacy applies the Bridge price. Confirm the $50 is being charged.
Worked example: what you'd actually pay
| Path (eligible member, Wegovy) | Monthly cost |
|---|---|
| Medicare GLP-1 Bridge | $50 (flat) |
| Manufacturer cash self-pay | ~$349 (maintenance) |
| TrumpRx self-pay portal | ~$199–$350 |
| Full retail (no coverage) | ~$1,349 |
For an eligible member, the Bridge is dramatically cheaper — roughly $600/year vs ~$4,200/year at the cash self-pay price. Compare all paths on cheapest GLP-1.
The catches (read before you count on it)
Weight-loss drugs only
Wegovy, Zepbound KwikPen, Foundayo — not the diabetes brands.
The $50 sits outside your cost-sharing
It doesn't count toward your deductible or the OOP cap.
No Extra Help on Bridge drugs
The Low-Income Subsidy can't be applied.
It's temporary
Scheduled to run only through December 31, 2027.
Don't confuse it with BALANCE
BALANCE is a separate model whose Medicare arm is not proceeding.
If you're not eligible
If you don't meet the Bridge criteria (or you want a diabetes drug it doesn't cover), you still have paths: if you have a qualifying medical condition, coverage for a non-weight-loss indication may apply (diabetes for Ozempic, cardiovascular risk for Wegovy, sleep apnea for Zepbound — see does Medicare cover Ozempic); or use cash-pay — the federal TrumpRx portal and manufacturer self-pay put GLP-1s in the ~$149–$350/month range.
This summarizes the CMS demonstration as of 2026-07-18; program details can change — confirm with CMS/Medicare and your Part D plan before relying on it. Educational only, not medical or insurance advice.